Search results for "Systemic inflammation"

showing 10 items of 93 documents

Prognostic Value of White Blood Cell Count in Acute Myocardial Infarction: Long-Term Mortality

2005

Although traditionally an elevated white blood cell count (WBC), an indicator of systemic inflammation, has been accepted as part of the healing response following acute myocardial infarction (AMI), it has frequently been shown to be a predictor of adverse cardiovascular events. The present study was designed to assess the association between WBC and long-term mortality in AMI patients either with ST-segment elevation (STEMI) or without ST-segment elevation (non-STEMI). Patients and method. The study included 1118 consecutive patients who were admitted with the diagnosis of AMI: 569 non-STEMI and 549 STEMI. The WBC was measured in the 24 hours following admission. Patients were divided into…

Malemedicine.medical_specialtyTime FactorsMyocardial InfarctionSystemic inflammationElectrocardiographyLeukocyte CountRisk FactorsInternal medicineWhite blood cellMyocardial RevascularizationmedicineHumansHospital Mortalitycardiovascular diseasesMyocardial infarctionAngioplasty Balloon CoronarySurvival analysisAgedProportional Hazards Modelsmedicine.diagnostic_testbusiness.industryProportional hazards modelHazard ratioGeneral MedicinePrognosismedicine.diseaseSurvival AnalysisSurgerysurgical procedures operativemedicine.anatomical_structureCardiologyRegression AnalysisFemaleLong term mortalitymedicine.symptombusinessElectrocardiographyFollow-Up StudiesRevista Española de Cardiología (English Edition)
researchProduct

Inflammation is an amplifier of lung congestion by high lv filling pressure in hemodialysis patients: a longitudinal study

2019

Introduction Since infammation alters vascular permeability, including vascular permeability in the lung, we hypothesized that it can be an amplifer of lung congestion in a category of patients at high risk for pulmonary oedema like end stage kidney disease (ESKD) patients. Objective and methods We investigated the efect modifcation by systemic infammation (serum CRP) on the relationship between a surrogate of the flling pressure of the LV [left atrial volume indexed to the body surface area (LAVI)] and lung water in a series of 220 ESKD patients. Lung water was quantifed by the number of ultrasound B lines (US-B) on lung US. Six-hundred and three recordings were performed during a 2-year f…

Nephrologymedicine.medical_specialtymedicine.medical_treatment030232 urology & nephrologyInflammationVascular permeabilityInfammation030204 cardiovascular system & hematologySystemic inflammation03 medical and health sciences0302 clinical medicineRenal DialysisPulmonary edemaInternal medicinemedicineHumansLongitudinal StudiesLung congestionESRDLungInflammationBody surface areaLungbusiness.industryCardiovascular riskPulmonary edemamedicine.diseasemedicine.anatomical_structureNephrologyHemodialysisCardiologyHemodialysismedicine.symptombusinessJournal of Nephrology
researchProduct

An unusual Erdheim-Chester disease with orbital involvement: a case report

2017

Erdheim-Chester disease is a rare non-Langerhans cell histiocytosis with multiorgan involvement and a specific tropism for perivascular and fatty connective tissue, of unclear origin, with poor response to therapy. Its identification is difficult because of the variable clinical presentation and its lack of knowledge. We report the case of a 63-years-old woman, with a history of bilateral orbital pseudotumor, who comes to our attention because of progressively worsening asthenia, vomiting and systemic inflammation. Total body computerized tomography scan showed a volumetric increase of choroid plexus of the temporal horn of the left lateral ventricle, presence of solid retrobulbar tissue at…

Pathologymedicine.medical_specialtySettore MED/09 - Medicina Internalcsh:MedicineConnective tissueDiseaseSystemic inflammationBilateral retro-orbital tumors; Erdheim-Chester disease; Multisystemic involvement; Non-Langerhans cell histiocytosis; Medicine (all)Non-Langerhans cell histiocytosismedicinemultisystemic involvement.Multisystemic involvementbilateral retro-orbital tumorsbusiness.industryMedicine (all)lcsh:RGeneral Medicinemedicine.diseaseHistiocytosismedicine.anatomical_structurenon-Langerhans cell histiocytosisErdheim–Chester diseaseVomitingErdheim-Chester diseaseBilateral retro-orbital tumorChoroid plexusNon-Langerhans cell histiocytosimedicine.symptombusinessItalian Journal of Medicine
researchProduct

Pentoxifylline and Oxypurinol: Potential Drugs to Prevent the “Cytokine Release (Storm) Syndrome” Caused by SARS-CoV-2?

2020

Background: COVID-19, caused by SARS-CoV-2, is a potentially lethal, rapidly-expanding pandemic and many efforts are being carried out worldwide to understand and control the disease. COVID-19 patients may display a cytokine release syndrome, which causes severe lung inflammation, leading, in many instances, to death. Objective: This paper is intended to explore the possibilities of controlling the COVID-19-associated hyperinflammation by using licensed drugs with anti-inflammatory effects. Hypothesis: We have previously described that pentoxifylline alone, or in combination with oxypurinol, reduces the systemic inflammation caused by experimentally-induced pancreatitis in rats. Pentoxifyl…

Pharmacology0303 health sciencesbusiness.industryInflammationmedicine.diseaseSystemic inflammationPentoxifyllineProinflammatory cytokine03 medical and health scienceschemistry.chemical_compoundCytokine release syndrome0302 clinical medicinechemistry030220 oncology & carcinogenesisDrug DiscoveryImmunologyMedicineAcute pancreatitisPancreatitismedicine.symptomXanthine oxidasebusiness030304 developmental biologymedicine.drugCurrent Pharmaceutical Design
researchProduct

Systemic inflammation in primary hypercholesterolemia results in platelet and leukocyte activation and their enhanced endothelial adhesiveness

2018

Primary hypercholesterolemiabusiness.industryApplied MathematicsGeneral MathematicsImmunologyMedicinePlateletmedicine.symptombusinessSystemic inflammationProceedings for Annual Meeting of The Japanese Pharmacological Society
researchProduct

Future Directions in the Pharmacologic Therapy of Chronic Obstructive Pulmonary Disease

2005

Current therapy for chronic obstructive pulmonary disease (COPD) fails to alter its relentless progression. This remains a significant challenge and unmet need. A recent advance is the demonstration that treatment with a fixed dose of an inhaled corticosteroid and a long-acting beta2-agonist in COPD improves lung function and quality of life, and reduces exacerbation more effectively than either drug alone. Other improvements include the introduction of tiotropium, a once-daily anticholinergic. In advanced clinical development are other once-daily bronchodilators and combinations of anticholinergic drugs and beta2-agonists. Increased understanding of the pathogenesis of COPD has led to nove…

Pulmonary and Respiratory MedicineDrugmedicine.medical_specialtyExacerbationPhosphodiesterase Inhibitorsmedicine.drug_classmedia_common.quotation_subjectAnti-Inflammatory AgentsPharmacologySystemic inflammationAntioxidantsPathogenesisPulmonary Disease Chronic ObstructiveAdministration InhalationAnticholinergicmedicineHumansProtease InhibitorsIntensive care medicineGlucocorticoidsmedia_commonCOPDInhalationbusiness.industryAntibodies MonoclonalAdrenergic beta-Agonistsmedicine.diseaseBronchodilator Agentsrespiratory tract diseasesDrug developmentQuality of LifeSmoking Cessationmedicine.symptombusinessProceedings of the American Thoracic Society
researchProduct

Obstructive sleep apnoea in acute coronary syndrome.

2019

Obstructive sleep apnoea (OSA) syndrome affects about 13% of the male and 7–9% of the female population. Hypoxia, oxidative stress and systemic inflammation link OSA and cardiovascular and metabolic consequences, including coronary artery disease. Current research has identified several clinical phenotypes, and the combination of breathing disturbances during sleep, systemic effects and end-organ damage might help to develop personalised therapeutic approaches. It is unclear whether OSA is a risk factor for acute coronary syndrome (ACS) and might affect its outcome. On the one hand, OSA in patients with ACS may worsen prognosis; on the other hand, OSA-related hypoxaemia could favour the dev…

Pulmonary and Respiratory MedicineMaleAcute coronary syndromemedicine.medical_specialtymedicine.medical_treatmentSettore MED/10 - Malattie Dell'Apparato Respiratorio030204 cardiovascular system & hematologySystemic inflammationCoronary artery disease03 medical and health sciences0302 clinical medicineRisk FactorsInternal medicinePositive airway pressurePrevalenceMedicineHumansContinuous positive airway pressureNon disponibiliAcute Coronary SyndromeAdverse effectLunglcsh:RC705-779Sleep Apnea ObstructiveContinuous Positive Airway Pressurebusiness.industryRespirationHemodynamicsSleep apnealcsh:Diseases of the respiratory systemHypoxia (medical)medicine.diseasenervous system diseasesrespiratory tract diseasesTreatment Outcome030228 respiratory systemCardiologyPatient ComplianceFemalemedicine.symptombusinessSleepEuropean respiratory review : an official journal of the European Respiratory Society
researchProduct

Impact of nutraceuticals on markers of systemic inflammation: Potential relevance to cardiovascular diseases - A position paper from the Internationa…

2021

Inflammation is a marker of arterial disease stemming from cholesterol-dependent to -independent molecular mechanisms. In recent years, the role of inflammation in atherogenesis has been underpinned by pharmacological approaches targeting systemic inflammation that have led to a significant reduction in cardiovascular disease (CVD) risk. Although the use of nutraceuticals to prevent CVD has largely focused on lipid-lowering (e.g, red-yeast rice and omega-3 fatty acids), there is growing interest and need, especially now in the time of coronavirus pandemic, in the use of nutraceuticals to reduce inflammatory markers, and potentially the inflammatory CVD burden, however, there is still not en…

RMArterial diseaseAnti-Inflammatory AgentsInflammationDiseaseC-reactive protein ; cardiovascular disease ; inflammation ; nutraceuticals ; omega-3 ; position paper ; red-yeast rice030204 cardiovascular system & hematologyBioinformaticsSystemic inflammationC-reactive protein03 medical and health sciences0302 clinical medicineNutraceuticalMedicineHumansPosition paper030212 general & internal medicineUncategorizedOmega-3InflammationbiologyC-reactive protein; Cardiovascular disease; Inflammation; Nutraceuticals; Omega-3; Position paper; Red-yeast rice; Anti-Inflammatory Agents; Biomarkers; Cardiovascular Diseases; Humans; Inflammation; Lipids; Dietary SupplementsVascular inflammationbusiness.industryC-reactive proteinC-reactive protein Cardiovascular disease Inflammation Nutraceuticals Omega-3 Position paper Red-yeast rice Anti-Inflammatory Agents Biomarkers Cardiovascular Diseases Humans Inflammation Lipids Dietary SupplementsCardiovascular diseaseRed-yeast riceLipidsCardiovascular DiseasesDietary Supplementsbiology.proteinPosition paperNutraceuticalsNutraceuticalmedicine.symptomCardiology and Cardiovascular MedicinebusinessBiomarkersProgress in cardiovascular diseases
researchProduct

Impact of probiotic Saccharomyces boulardii on the gut microbiome composition in HIV-treated patients: A double-blind, randomised, placebo-controlled…

2017

Dysbalance in gut microbiota has been linked to increased microbial translocation, leading to chronic inflammation in HIV-patients, even under effective HAART. Moreover, microbial translocation is associated with insufficient reconstitution of CD4+T cells, and contributes to the pathogenesis of immunologic non-response. In a double-blind, randomised, placebo-controlled trial, we recently showed that, compared to placebo, 12 weeks treatment with probiotic Saccharomyces boulardii significantly reduced plasma levels of bacterial translocation (Lipopolysaccharide-binding protein or LBP) and systemic inflammation (IL-6) in 44 HIV virologically suppressed patients, half of whom (n = 22) had immun…

RNA virusesMale0301 basic medicinePlacebo-controlled studylcsh:MedicineHIV InfectionsGut floraPathology and Laboratory MedicineSystemic inflammationlaw.inventionPlacebosProbiotic0302 clinical medicineImmunodeficiency ViruseslawMedicine and Health SciencesMedicinelcsh:ScienceImmune ResponseMultidisciplinarybiologyMicrobiotaGenomicsMiddle AgedProbiòticsBacterial PathogensIntestinesSaccharomyces boulardiiMedical MicrobiologyViral PathogensVirusesFemale030211 gastroenterology & hepatologyPathogensmedicine.symptomResearch ArticleSaccharomyces boulardiiAdultImmunologyMicrobial GenomicsMicrobiologySaccharomyces03 medical and health sciencesSigns and SymptomsImmune systemDouble-Blind MethodDiagnostic MedicineRetrovirusesGeneticsVIH (Virus)HumansMicrobiomeMicrobial PathogensInflammationClostridiumBacteriabusiness.industryProbioticsGut BacteriaLentivirusLachnospiraceaelcsh:ROrganismsFungiBiology and Life SciencesHIVbiology.organism_classificationYeast030104 developmental biologyImmunologylcsh:QMicrobiomebusinessPLoS ONE
researchProduct

Factors contributing to the variability in muscle ageing

2012

a b s t r a c t Ageing is accompanied with a progressive loss of muscle mass and force generating capacity. Ultimately, the muscle wasting and weakness may dramatically impact on mobility and the quality of life, where the elderly has increasing problems with performing activities of daily life, such as rising from a chair or climbing stairs. The rate of structural and functional deterioration of muscle appears to vary considerably between people. Part of the variation in the 'rate of muscle ageing' is attributable to genetic factors, the timing of changes in circulating hormones and the presence or absence of chronic low-grade systemic inflammation. Where an individual cannot change much i…

SarcopeniaWeaknessmedicine.medical_specialtyInflammationSystemic inflammationGeneral Biochemistry Genetics and Molecular BiologyMicrocirculationInternal medicineActivities of Daily LivingmedicineHumansMobility LimitationMuscle SkeletalExerciseWastingInflammationMuscle Weaknessbusiness.industryObstetrics and GynecologyMuscle weaknessHormonesCapillariesEndocrinologyAgeingmedicine.symptomEnergy IntakebusinessHormoneMaturitas
researchProduct